Nancy Simonian
2021
In 2021, Nancy Simonian earned a total compensation of $3.1M as President & Chief Executive Officer at Syros Pharmaceuticals, a 23% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $322,905 |
---|---|
Option Awards | $2,163,749 |
Salary | $615,923 |
Other | $576 |
Total | $3,103,153 |
Simonian received $2.2M in option awards, accounting for 70% of the total pay in 2021.
Simonian also received $322.9K in non-equity incentive plan, $615.9K in salary and $576 in other compensation.
Rankings
In 2021, Nancy Simonian's compensation ranked 4,301st out of 12,415 executives tracked by ExecPay. In other words, Simonian earned more than 65.4% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 4,301 | 65th |
Manufacturing | 1,776 | 68th |
Chemicals And Allied Products | 744 | 69th |
Drugs | 664 | 68th |
Pharmaceutical Preparations | 471 | 70th |
Simonian's colleagues
We found three more compensation records of executives who worked with Nancy Simonian at Syros Pharmaceuticals in 2021.
News
Syros Pharmaceuticals CEO Nancy Simonian's 2023 pay falls 59% to $1.4M
April 23, 2024
Syros Pharmaceuticals CEO Nancy Simonian's 2022 pay rises 12% to $3.5M
April 21, 2023
Syros Pharmaceuticals CEO Nancy Simonian's 2021 pay jumps 23% to $3.1M
April 21, 2022
Syros Pharmaceuticals CEO Nancy Simonian's 2020 pay falls 30% to $2.5M
April 29, 2021
Syros Pharmaceuticals CEO Nancy Simonian's 2019 pay rises 19% to $3.6M
April 28, 2020
Syros Pharmaceuticals CEO Nancy Simonian's 2018 pay jumps 36% to $3M
April 25, 2019